Statin intolerance

Circulation

Volumn 131, Issue 13, 2015, Pages e389-e391

  Fitchett, David H ^a,b,d   Hegele, Robert A ^e   Verma, Subodh ^a,b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL CRAMP; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CATARACT; DIABETES MELLITUS; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ERECTILE DYSFUNCTION; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY INJURY; LIVER FUNCTION; LIVER INJURY; LONG TERM SURVIVAL; LUNG DISEASE; MENTAL DISEASE; MUSCLE ACHE; MUSCLE CRAMP; MUSCLE FUNCTION; MYALGIA; MYOSITIS; NEOPLASM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIET THERAPY; DRUG EFFECTS; DRUG SUBSTITUTION; DRUG-INDUCED LIVER INJURY; EVIDENCE BASED MEDICINE; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; LONGEVITY; LOW FAT DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIET, FAT-RESTRICTED; DRUG SUBSTITUTION; DRUG-INDUCED LIVER INJURY; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TESTS; LONGEVITY; MYALGIA; RHABDOMYOLYSIS; RISK FACTORS;

EID: 84929307305     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013189     Document Type: Article

References (8)

1. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
2. Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29:1553-1568. doi: 10.1016/j.cjca.2013.09.023.
3. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral haemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012;43:2149-2156.
4. Ott B, Daiello L, Springate B, Bixby K, Murali M, Dahabreh I, Trikalinos T. Do statin drugs impair cognition? A systematic review and meta-analysis. Alzheimers Dement 2013;9:P666.
5. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526-534. doi: 10.7326/0003-4819-158-7-201304020-00004.
6. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022-1036. doi: 10.1161/CIRCRESAHA.114.301621.
7. Tomkin GH, Owens D. Investigational therapies for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2014;23:1411-1421. doi: 10.1517/13543784.2014.922950.
8. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151-167. doi: 10.1016/j.cjca.2012.11.032.